Medallion Wealth Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Medallion Wealth Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-140	Closed	-$2.59K	–	1296
2026 Q1	$2.59K	Hold	140	–	–	﹤0.01%	966
2025 Q4	$2.18K	Hold	140	–	–	﹤0.01%	980
2025 Q3	$2.05K	Hold	140	–	–	﹤0.01%	973
2025 Q2	$2.16K	Hold	140	–	–	﹤0.01%	949
2025 Q1	$2.08K	Sell	140 -425	-75%	-$5.96K	﹤0.01%	911
2024 Q4	$7.71K	Buy	+565	New	+$7.76K	﹤0.01%	706

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Medallion Wealth Advisors's TAK Position: Q2 2026 in Review

Medallion Wealth Advisors sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 140 shares — an estimated $2.59K sold.

Medallion Wealth Advisors first reported a position in TAK in Q4 2024 and held it in 6 quarters. The position peaked at $7.71K in Q4 2024. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Medallion Wealth Advisors reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Medallion Wealth Advisors sold 140 Takeda Pharmaceutical shares in Q2 2026, an estimated $2.59K.
Medallion Wealth Advisors first reported a position in Takeda Pharmaceutical in Q4 2024 and held it in 6 quarters.
Medallion Wealth Advisors's Takeda Pharmaceutical position peaked at $7.71K in Q4 2024.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.